-
NEWS RELEASE
2021.11.24
Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ mouse model.
-
UPCOMING EVENTS
SMC announces Presentation of New Data at the KDDW 2021
2021.10.27
We are pleased to announce the acceptance of our abstracts, “Molecular Pathogenesis of Non-Alcoholic Steatohepatitis (NASH) through the Dysregulation of Metabolic Organ Network in the NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet” and "RNA-Seq Analysis of Liver from NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet"—KDDW 2021, to be held from November 18 to 20, 2021.
-
PRESS RELEASES
STZ: Type 1 or Type 2 Diabetes?
2021.10.08
When discussing our unique NASH-HCC model STAM with clients, we are so often asked: What type of diabetes does the streptozotocin induce?
-
UPCOMING EVENTS
Reserve a non-clinical pharmacology consultation with us at BioPharm America!
2021.09.15
We are joining BioPharm America™ Digital, one of the most famous virtual biotech partnering and education events.
-
UPCOMING EVENTS
2021.09.07
We will be attending the annual 24th BioJapan from Wednesday, October 13th, 2021 – Friday, October 15th, 2021 (10/13 – 15, 2021) at the Pacifico Yokohama Convention Center!
-
NEWS RELEASE
2021.08.31
COVID-19 is now being recognized as a multi-organ disease that causes not only pneumonia, but also cause damage to other organs such as the liver, kidney and intestines.
-
NEWS RELEASE
2021.08.13
ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks.
-
PUBLICATION
National Defense Medical College's publication in Surgery Open Science
2021.08.04
SMC announces that National Defense Medical College (Japan) has published the results of a study using STAM™ mouse model in Surery Open Science.
-
UPDATE
2021.07.20
We recently made a presentation on our STAM™ mouse at the 81st Annual Meeting of the American Diabetes Association (June 25 to 29, 2021).
-
PRODUCTS AND SERVICES
Introducing our new model: Liver Orthotopic Xenograft mouse model
2021.07.01
We’re getting in touch today with an announcement regarding the addition of the Liver Orthotopic Xenograft mouse model to our model line-up – a cancer model that also allows the evaluation of the tumor microenvironment.
-
PUBLICATION
Our clients’ presentations at DDW 2021
2021.06.22
Our clients presented data on treatment of NASH using STAMTM model at the DDW2021 (May 21-23).
-
UPCOMING EVENTS
2021.06.08
We are pleased to announce the acceptance of our abstract, “RNA-seq Analysis of Liver from Diabetic and NASH Model Mouse Treated with Streptozotocin, High-Fat Diet”, for presentation in the category “Integrated Physiology—Liver” at the 81st Annual Meeting of the American Diabetes Association, to be held from June 25 to 29, 2021.